secwatch.observer — SEC 8-K summary
======================================

Issuer:     EAGLE PHARMACEUTICALS, INC. (—)
CIK:        0000827871
Form:       8-K
Filed at:   2023-11-29T23:59:59+00:00
Accession:  0001104659-23-121842
Event type: leadership
Sentiment:  neutral
Materiality: 0.80
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Eagle Pharmaceuticals CEO Scott Tarriff resigns; Chairman Michael Graves named Interim Executive Chairman
--------------------------------------------------------------------------------

- Scott Tarriff resigns as President, CEO, and Director effective Nov 27, 2023; will serve as consultant starting Jan 1, 2024.
- Michael Graves appointed Interim Executive Chairman and Interim Principal Executive Officer; CEO search initiated.
- Board reduced from seven to six members; committee assignments realigned.
- Tarriff receives severance: 18-month base salary lump sum, target bonus, COBRA for 18 months, and $20k/month consulting retainer.
- Equity vesting acceleration for time-vesting awards; performance-vesting 2021 PSUs remain eligible during consulting period.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/827871/000110465923121842/0001104659-23-121842-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/827871/000110465923121842/tm2331615d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-121842

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer